When should a Vascath (non‑tunneled dialysis catheter) be used versus a central venous line and a permacath (tunneled cuffed dialysis catheter) for hemodialysis access?

Vascular Access Selection for Hemodialysis

Use a non-tunneled catheter (Vascath) only for urgent/temporary access lasting less than 2 weeks; transition to a tunneled catheter (Permacath) if dialysis will continue beyond 2 weeks; and plan for arteriovenous access (fistula or graft) as the definitive solution to minimize infection, hospitalization, and mortality risks.

Decision Algorithm

Immediate Access Needs (< 2 weeks)

• Non-tunneled catheter (Vascath) is appropriate for urgent hemodialysis initiation 1
• Preferred site: right internal jugular vein 2
• Use ultrasound guidance to reduce mechanical complications 2
• This is strictly a bridge solution—infection risk escalates rapidly beyond 2 weeks 1

Short-term Access (2 weeks to 3 months)

• Tunneled catheter (Permacath) is the clear choice over non-tunneled catheters due to significantly lower infection risk 1
• Recent data shows tunneled catheters have longer survival (66.9 vs 57.9 days, p=0.001) compared to non-tunneled catheters 3
• Infection rates are comparable between tunneled and non-tunneled catheters at 6 weeks, but tunneled catheters demonstrate superior survival beyond this timepoint 3

Valid indications for tunneled catheters include:

• AVF/AVG created but not yet mature for use
• Acute transplant rejection requiring temporary dialysis
• Living donor transplant confirmed within 90 days
• AVF/AVG complication requiring temporary alternative access 1

Long-term Strategy (> 3 months)

• Convert to arteriovenous access (fistula preferred, then graft) whenever anatomically feasible 1
• Tunneled catheters carry higher infection rates, thrombosis risk, and mortality compared to arteriovenous access 4
• Most incident hemodialysis patients starting with a catheter should convert to AVF or AVG to reduce infection/bacteremia and infection-related hospitalizations 1

Critical Distinctions

"Central line" terminology requires clarification: In dialysis contexts, this typically refers to either non-tunneled or tunneled catheters. Standard central venous catheters used for medications/fluids are inadequate for hemodialysis due to insufficient flow rates.

Tunneled vs Non-tunneled Catheters:

• Tunneling creates a subcutaneous tract with a cuff that promotes tissue ingrowth, creating a mechanical and antimicrobial barrier
• This design feature is why tunneled catheters have lower infection rates and can remain in place for weeks to months 1, 4

Common Pitfalls

1. Leaving non-tunneled catheters beyond 2 weeks: This dramatically increases infection risk without benefit 1

2. Accepting long-term catheter use when AVF/AVG is feasible: Catheters should always be considered third-line access—mortality and morbidity are demonstrably higher than with arteriovenous access 4

3. Placing catheters on the same side as a planned fistula: Insert catheters on the opposite side to preserve venous anatomy for future AVF creation 2

4. Delaying AVF planning: Even when starting with a catheter, simultaneous planning for arteriovenous access is essential to minimize catheter exposure time 1

Site Selection Priority

1. Right internal jugular vein (first choice for both tunneled and non-tunneled) 2
2. Left internal jugular vein
3. Femoral vein (acceptable for non-tunneled in acute kidney injury) 2
4. Avoid subclavian veins when possible—risk of central venous stenosis compromises future AVF options